WO2022202985A1 - ペプチド、及び該ペプチドを有効成分として含有する組成物 - Google Patents
ペプチド、及び該ペプチドを有効成分として含有する組成物 Download PDFInfo
- Publication number
- WO2022202985A1 WO2022202985A1 PCT/JP2022/013912 JP2022013912W WO2022202985A1 WO 2022202985 A1 WO2022202985 A1 WO 2022202985A1 JP 2022013912 W JP2022013912 W JP 2022013912W WO 2022202985 A1 WO2022202985 A1 WO 2022202985A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- present technology
- amino acid
- test
- acid sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 130
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 239000004480 active ingredient Substances 0.000 title claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 235000013305 food Nutrition 0.000 claims description 42
- 230000001430 anti-depressive effect Effects 0.000 claims description 21
- 230000000949 anxiolytic effect Effects 0.000 claims description 17
- 208000019901 Anxiety disease Diseases 0.000 claims description 13
- 230000006872 improvement Effects 0.000 claims description 12
- 201000003723 learning disability Diseases 0.000 claims description 12
- 208000020358 Learning disease Diseases 0.000 claims description 9
- 208000026139 Memory disease Diseases 0.000 claims description 9
- 208000019116 sleep disease Diseases 0.000 claims description 9
- 208000020925 Bipolar disease Diseases 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 description 49
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 44
- 230000009471 action Effects 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 238000000034 method Methods 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 108010046377 Whey Proteins Proteins 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000000935 antidepressant agent Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 230000007958 sleep Effects 0.000 description 15
- 102000007544 Whey Proteins Human genes 0.000 description 14
- 229940005513 antidepressants Drugs 0.000 description 14
- 230000000049 anti-anxiety effect Effects 0.000 description 13
- 238000002372 labelling Methods 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 239000002249 anxiolytic agent Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 229940076279 serotonin Drugs 0.000 description 12
- 235000021119 whey protein Nutrition 0.000 description 12
- 239000004365 Protease Substances 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 230000013016 learning Effects 0.000 description 10
- 206010027175 memory impairment Diseases 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- -1 sleep-improving Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000006399 behavior Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 102000004157 Hydrolases Human genes 0.000 description 7
- 108090000604 Hydrolases Proteins 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 230000036506 anxiety Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000003678 AMPA Receptors Human genes 0.000 description 6
- 108090000078 AMPA Receptors Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000004278 EU approved seasoning Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000011194 food seasoning agent Nutrition 0.000 description 5
- 235000013611 frozen food Nutrition 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229940098747 AMPA receptor antagonist Drugs 0.000 description 4
- 239000000775 AMPA receptor antagonist Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical class [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 238000012346 open field test Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000019256 formaldehyde Nutrition 0.000 description 2
- 229960004279 formaldehyde Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000003727 serotonin 1A antagonist Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010048744 Fear of falling Diseases 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 240000005856 Lyophyllum decastes Species 0.000 description 1
- 235000013194 Lyophyllum decastes Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YBHQCJILTOVLHD-YVMONPNESA-N Mirin Chemical compound S1C(N)=NC(=O)\C1=C\C1=CC=C(O)C=C1 YBHQCJILTOVLHD-YVMONPNESA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- UMTDAKAAYOXIKU-UHFFFAOYSA-N N-tert-butyl-3-[4-(2-methoxyphenyl)-1-piperazinyl]-2-phenylpropanamide Chemical compound COC1=CC=CC=C1N1CCN(CC(C(=O)NC(C)(C)C)C=2C=CC=CC=2)CC1 UMTDAKAAYOXIKU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000001353 anxiety effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012813 breadcrumbs Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012839 cake mixes Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 235000014613 canned/preserved soup Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000006912 hydrolase reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 235000014109 instant soup Nutrition 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 108010009355 microbial metalloproteinases Proteins 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108010043393 protease N Proteins 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to peptides and compositions containing the peptides as active ingredients.
- Patent Document 1 discloses peptides in which hydrophobic amino acids are adjacent to tyrosine, phenylalanine, tryptophan, or histidine as peptides having anxiolytic effects.
- Patent Document 2 describes (i) amino acid sequence LSSTQAQQSY, (ii) amino acid sequence LSSTQAQQSW, or (iii) amino acid sequence as peptides for improving or treating low motivation, depression or depressive mood disorders or symptoms based on them. Peptides consisting of any of the sequences LSSTQAQQSF are disclosed.
- the main purpose of the present technology is to provide a peptide having various actions, which can be easily ingested on a daily basis and has few side effects, and a composition containing the peptide as an active ingredient.
- a peptide consisting of the following amino acid sequence (a) or (b) is provided.
- the present technology also provides a composition containing the peptide as an active ingredient.
- the composition according to the present technology may be food or drink.
- a composition according to the present technology may be a pharmaceutical.
- the composition according to the present technology may be used to treat, prevent and/or improve depression, bipolar disorder, schizophrenia, anxiety, or sleep disorders.
- the peptide NLPPLT has excellent anti-anxiety effects, sleep-improving effects, anti-depressive effects, and improving effects on learning disorders and/or memory disorders
- various An active peptide and a composition containing the peptide as an active ingredient can be provided. Note that the effects described here are not necessarily limited, and may be any of the effects described in this specification.
- the peptide according to the present technology has an amino acid sequence (SEQ ID NO: 1) represented by Asn-Leu-Pro-Pro-Leu-Thr.
- Asn (N) indicates an L-asparagine residue
- Leu (L) an L-leucine residue
- Pro (P) an L-proline residue
- Thr (T) an L-threonine residue.
- the peptide according to the present technology has an amino acid string in which one or several amino acids are substituted, deleted, or added to the amino acid sequence shown in SEQ ID NO:1. In this case, the number of amino acids to be substituted, deleted or added is preferably 2 or less.
- the peptide according to the present technology has one or more actions selected from anxiolytic action, sleep improvement action, antidepressant action, and action for improving learning impairment and/or memory impairment.
- a single amino acid may be substituted, deleted, or added.
- the peptide according to the present technology may be a salt of peptide NLPPLT. Examples of the salts include alkali metals such as potassium and sodium; alkaline earth metals such as calcium and magnesium;
- Examples of methods for producing peptide NLPPLT include, but are not limited to, the following methods. Specifically, for example, a protein or peptide containing an amino acid sequence represented by Asn-Leu-Pro-Pro-Leu-Thr (SEQ ID NO: 1) is decomposed by hydrolysis or the like, and separated from the resulting decomposed product.
- Method of obtaining by purification Method of synthesizing peptide NLPPLT by a peptide chemical synthesis method and then separating and purifying peptide NLPPLT from the resulting synthetic product; Plants and animals that produce peptide NLPPLT and peptides containing the same and a method of extracting from microorganisms and separating and purifying from the obtained extract.
- Peptides according to the present technology can be produced, for example, by appropriately hydrolyzing proteins such as whey proteins with acids, alkalis, enzymes, or the like.
- a method for obtaining the peptide NLPPLT by hydrolyzing the raw material protein with a hydrolase is exemplified below.
- the protein is dissolved, dispersed or suspended in water before hydrolyzing the raw material protein with an enzyme.
- the raw material protein is not particularly limited as long as it is a protein containing the peptide according to the present technology in its structure and can produce the peptide according to the present technology when appropriately digested with a hydrolase.
- the protein include those derived from animals, plants, and microorganisms, and in the present technology, whey protein, which is available in large quantities, is preferred.
- the whey protein may be a commercially available product, or a whey protein concentrate, a whey protein isolate, or a whey protein isolate separated and purified from whey protein by a conventional method (e.g., ultrafiltration, ion exchange method, etc.).
- whey protein and whey eg, whey powder, desalted whey powder, etc.
- the treatment method differs depending on the properties of the raw material protein. If the raw material protein is soluble, the raw material protein may be dispersed in water or warm water and dissolved. The protein may be homogenized by mixing and stirring.
- an alkaline agent or an acid agent may be added to the solution containing the protein to adjust the pH. This pH is preferably adjusted to or near the optimum pH for the hydrolase to be used.
- the alkali agent or acid agent is not particularly limited, and those acceptable for pharmaceuticals or food and drink may be used.
- alkaline agents include hydroxides such as sodium hydroxide and calcium hydroxide; carbonates such as potassium carbonate; and these may be alkali metal salts or alkaline earth metal salts.
- acid agents include inorganic acids such as hydrochloric acid and phosphoric acid; and organic acids such as citric acid, acetic acid and formic acid. In the present technology, one or more of these can be used as appropriate.
- it is preferable to sterilize the solution containing the protein by heating at 70 to 90° C. for about 15 seconds to 10 minutes from the viewpoint of preventing spoilage due to contamination with various bacteria.
- a predetermined amount of hydrolase is added to the solution containing the protein and reacted at a temperature of about 10 to 85° C. for 0.1 to 48 hours to obtain a hydrolyzate.
- the solution is maintained at an appropriate temperature, for example, 30 to 60° C., preferably 45 to 55° C., depending on the type of enzyme, to initiate protein hydrolysis. do.
- the reaction may be continued until the desired decomposition rate is reached while monitoring the decomposition rate of the enzymatic reaction.
- the hydrolase reaction is terminated, for example, by deactivating the enzyme in the hydrolyzate, and can be performed by a conventional heat deactivation treatment.
- the heating temperature and holding time of the heat deactivation treatment can be appropriately set in consideration of the thermal stability of the enzyme used, and the conditions that can be sufficiently deactivated can be set as appropriate.
- the temperature range is 80 to 130 ° C. for 30 minutes. Hold times of ⁇ 2 seconds can be performed.
- the hydrolase is not particularly limited, it is preferably an enzyme that can hydrolyze the raw material protein to generate the peptide according to the present technology. Moreover, you may use a hydrolase individually or in combination of 2 or more types. When using two or more enzymes, each enzymatic reaction may be carried out simultaneously or separately. Specifically, it is preferable to use endopeptidase, trypsin, and papain in combination as the enzymes that can be generated, and it is more preferable to use a mixture of these three types of enzymes.
- endopeptidase examples include those derived from microorganisms and animals, and specific examples include protease derived from Bacillus subtilus and protease derived from animal pancreas.
- Commercially available products can be used as the protease.
- commercially available proteases include Bacillus-derived proteases such as Protease N Amano (manufactured by Amano Enzymes), Bioplase SP-20 (manufactured by Nagase & Co.), and Neutrase (manufactured by Novozymes Japan); Animal pancreas-derived proteases such as OS (manufactured by Novozymes Japan) and the like can be mentioned.
- Examples of the trypsin include PTN6.0S (manufactured by Novozymes Japan) and the like, and examples of the papain include papain W-40 (manufactured by Amano Enzymes) and purified papain (manufactured by Mitsubishi Chemical). etc.
- the decomposition rate of the raw material protein is calculated by measuring the total nitrogen content of the sample by the Kjeldahl method, measuring the formol nitrogen content of the sample by the formol titration method, and calculating the decomposition rate from these measured values by the following formula (1 ).
- peptides according to the present technology it is preferable to isolate or purify the peptide according to the present technology from the hydrolyzate.
- Purification of peptides according to the present technology can be performed by the same techniques as those usually used for oligopeptide purification, such as ion-exchange chromatography, adsorption chromatography, reversed-phase chromatography, partition chromatography, and gel filtration chromatography.
- Various chromatographic methods such as solvent precipitation, salting out, and partitioning between two liquid phases can be appropriately combined.
- the fraction containing the target substance can be determined using the aforementioned various actions as indicators. Also, the active components of those fractions can be identified by mass spectrometry.
- Peptides according to the present technology can also be produced by chemical synthesis.
- Chemical synthesis of peptides according to the present technology can be performed by a liquid-phase method or a solid-phase method that is commonly used for synthesis of oligopeptides.
- the synthesized peptide is deprotected, if necessary, and unreacted reagents, by-products, etc. are removed to isolate the peptide according to the present technology.
- Synthesis of such peptides can be performed, for example, using a commercially available peptide synthesizer or the like.
- Obtaining the peptide of interest should be confirmed by using as an index any one or more actions selected from anxiolytic action, sleep improving action, antidepressant action, and improving action on learning and/or memory impairment. can be done.
- Peptide NLPPLT has an anti-anxiety effect as shown in Test Example 1 described later, and also has an effect via activation of serotonin 5-HT 1A receptor as shown in Test Example 2 described later, thus improving sleep. also has an effect. In addition, as shown in Test Example 3 below, it also has an antidepressant effect.
- the serotonin 5-HT 1A receptor is the most widely expressed of the various serotonin receptors and is involved in behaviors such as sleep, feeding, thermoregulation and anxiety. Therefore, it is conventionally known that activation of this serotonin 5-HT 1A receptor produces one or more actions selected from anxiolytic action, sleep improving action and antidepressant action. Therefore, the peptide according to the present technology can be used for anti-anxiety, sleep improvement, or anti-depression.
- the peptides according to the present technology can prevent, ameliorate, or treat various diseases and symptoms associated with serotonin 5-HT 1A receptors. Therefore, the peptide according to the present technology is used for methods of preventing, ameliorating and/or treating diseases and symptoms associated with serotonin 5-HT 1A receptors by ingesting or administering to animals including humans. can be used as an active ingredient.
- the term "improvement” refers to amelioration of a disease, symptom or condition; prevention or delay of worsening of a disease, symptom or condition; reversal, prevention or delay of progression of a disease or symptom; means preventing or delaying the onset of a disease or condition in an applicable subject, reducing the risk of a disease or symptom in an applicable subject, or maintaining health.
- Various diseases and symptoms associated with the serotonin 5-HT 1A receptor include, for example, depression, bipolar disorder, schizophrenia, anxiety neurosis, and sleep disorders.
- the peptide NLPPLT has an action mediated by AMPA receptor activation.
- AMPA receptors are a kind of glutamate receptors, are widely distributed in the central nervous system, and are known to be greatly involved in memory and learning. Therefore, it is conventionally known that activation of the AMPA receptor not only produces an antidepressant effect but also an ameliorating effect on learning impairment and/or memory impairment. Therefore, the peptide according to the present technology can be used not only for anti-anxiety, sleep improvement, or anti-depression, but also for improving learning disorders and/or memory disorders.
- non-therapeutic purpose is a concept that does not include medical practice, that is, treatment of the human body by treatment, and includes, for example, beauty practices and health promotion.
- compositions also provides a composition containing the aforementioned peptide according to the present technology as an active ingredient.
- the composition according to the present technology can be used as pharmaceuticals such as formulations, food and drink, feed, and the like.
- the peptide according to the present technology can be used for producing these various compositions.
- composition according to the present technology may be used in combination with any component, if necessary, in addition to the peptide according to the present technology.
- ingredients that are allowed in pharmaceuticals, food and drink, feeds, and the like can be used as appropriate.
- composition according to the present technology when used in pharmaceuticals, it can be prepared by adding the peptide according to the present technology to known pharmaceuticals, or new pharmaceuticals can be produced by mixing the peptides into raw materials for pharmaceuticals. can also In addition, when the peptide according to the present technology is used for pharmaceuticals, it may be used as it is, after being concentrated, or after being processed into a solid, liquid, granule, or powder form.
- the drug can be appropriately formulated into a desired dosage form according to an administration method such as oral administration or parenteral administration.
- the dosage form is not particularly limited, but in the case of oral administration, for example, solid preparations such as powders, granules, tablets, troches, and capsules; liquid preparations such as solutions, syrups, suspensions, emulsions, etc. can be
- parenteral administration for example, it can be formulated into suppositories, sprays, inhalants, ointments, patches, injections, and the like.
- formulation can be suitably implemented by a well-known method according to a dosage form.
- a pharmaceutical carrier When formulating, it may be formulated by adding a pharmaceutical carrier as appropriate.
- ingredients such as excipients, pH adjusters, colorants, and corrigents that are usually used for formulation can be used.
- ingredients having known or future therapeutic, preventive and/or ameliorative effects on diseases and symptoms can also be used in combination.
- organic or inorganic carriers can be used as pharmaceutical carriers depending on the dosage form.
- carriers for solid preparations include excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents and the like.
- Excipients include, for example, sugar derivatives such as lactose, sucrose, glucose, mannitol, sorbitol; starch derivatives such as corn starch, potato starch, ⁇ -starch, dextrin, carboxymethyl starch; crystalline cellulose, hydroxypropyl cellulose, Hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose derivatives such as carboxymethylcellulose calcium; gum arabic; dextran; pullulan; silicate derivatives such as light silicic anhydride, synthetic aluminum silicate, and magnesium aluminometasilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium; sulfate derivatives such as calcium sulfate;
- binders examples include gelatin; polyvinylpyrrolidone; macrogol, etc., in addition to the above excipients.
- disintegrants include, in addition to the above excipients, chemically modified starch or cellulose derivatives such as croscarmellose sodium, carboxymethyl starch sodium, and crosslinked polyvinylpyrrolidone.
- Lubricants include, for example, talc; stearic acid; metal stearates such as calcium stearate and magnesium stearate; colloidal silica; waxes such as pea gum and gairou; ; carboxylic acid sodium salts such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acid anhydride and silicic acid hydrate; be done.
- stabilizers include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; acetic anhydride; and sorbic acid.
- Flavoring agents include, for example, sweeteners, acidulants, flavoring agents, and the like.
- the carrier used includes a solvent such as water, a flavoring agent, and the like.
- the peptide according to the present technology can be added to a known food or drink, or a new food or drink can be prepared by mixing the peptide with the ingredients of the food or drink. You can also manufacture products. Moreover, when the peptide according to the present technology is used in food and drink, it may be used as it is, after being concentrated, or after being processed into a solid, liquid, granule, or powder form.
- Food and drink include tablets, liquid foods, feeds (including pets), regardless of whether they are liquid, paste, solid, or powder, as well as flour products, instant foods, processed agricultural products, and marine products.
- Examples include processed products, processed livestock products, milk/dairy products, oils and fats, basic seasonings, compound seasonings/foods, frozen foods, confectionery, beverages, and other commercially available foods.
- dairy products include fermented milk, milk drinks, lactic acid bacteria drinks, sweetened condensed milk, skim milk powder, sweetened milk powder, modified milk powder, cream, cheese, butter, and ice creams.
- Wheat flour products include, for example, bread, macaroni, spaghetti, noodles, cake mixes, fried chicken flour, and bread crumbs.
- instant foods include instant noodles, cup noodles, retort/cooked foods, cooked canned foods, microwave oven foods, instant soups/stews, instant miso soups/soup, canned soups, freeze-dried foods, and other instant foods. be done.
- processed agricultural products include canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, and cereals (processed grain products).
- processed marine products include canned marine products, fish ham and sausages, fish paste products, marine delicacies, and tsukudani.
- processed livestock products include canned livestock products, pastes, livestock hams, sausages, and the like.
- Fats and oils include, for example, butter, margarines, and vegetable oils.
- Basic seasonings include, for example, soy sauce, miso, sauces, processed tomato seasonings, mirin, and vinegars. Examples include dressings, noodle soups, spices, and other compound seasonings.
- Frozen food includes, for example, material frozen food, half-cooked frozen food, cooked frozen food, and the like.
- Confectionery includes, for example, caramels, candies, chewing gums, chocolates, cookies, biscuits, cakes, pies, snacks, crackers, Japanese confections, rice confections, bean confections, dessert confections, and other confectionery.
- beverages include carbonated drinks, natural fruit juices, fruit juice drinks, soft drinks containing fruit juice, pulp drinks, fruit drinks containing fruit, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powdered drinks, and concentrated drinks.
- sports drinks, nutritional drinks, alcoholic beverages, and other beverages of choice include baby food, furikake, ochazuke seaweed, and the like.
- the food and drink defined by the present technology are provided and provided as food and drink labeled with insurance uses (for example, for anti-anxiety, sleep improvement, anti-depression, learning disability and/or memory impairment improvement, etc.). can be sold.
- insurance uses for example, for anti-anxiety, sleep improvement, anti-depression, learning disability and/or memory impairment improvement, etc.
- the act of "display” includes all acts for informing the consumer of the above-mentioned use, and if it is an expression that can remind or analogize the above-mentioned use, the purpose of the display, the display Regardless of the content, the object or medium to be displayed, all fall under the "display" act of this technology.
- the "indication" be expressed in such a way that the consumer can directly recognize the use.
- the act of transferring, handing over, displaying for the purpose of transfer or delivery, importing products related to food and beverages or product packaging that describes the above-mentioned use, advertisements related to products, price lists or transaction documents Examples include the act of displaying or distributing information with the use described therein, or providing information containing such information with the use described therein by electromagnetic means (for example, the Internet, etc.).
- the content of the display is a display approved by the government (for example, a display that is approved based on various systems established by the government and performed in a manner based on such approval).
- a display that is approved based on various systems established by the government and performed in a manner based on such approval.
- labeling includes health food, functional food, food for the sick, enteral nutritional food, food for special dietary uses, food with health claims, food for specified health use, food with function claims, food with nutrient function claims, and medical products. Display as an off-the-shelf item is also possible.
- labeling approved by the Consumer Affairs Agency for example, labeling approved by the Foods for Specified Health Uses system, the Foods with Function Claims system, and similar systems can be mentioned. More specifically, labeling as food for specified health use, labeling as food for specified health use with certain conditions, labeling as food with function claims, labeling to the effect that it affects the structure and function of the body, labeling to reduce disease risk, etc. can be mentioned.
- a typical example is labeling as a food for specified health use (especially, labeling of health use) specified in the Ordinance for Enforcement of the Health Promotion Law (Ministry of Health, Labor and Welfare Ordinance No. 86 of April 30, 2003). ), labeling as food with function claims stipulated in the Food Labeling Law (Law No. 70 of 2013) and similar labeling.
- the words used to display the above-mentioned are only words such as "for anti-anxiety”, “for improving sleep”, “for anti-depression”, “for improving learning disorders and/or memory disorders”. It is not limited, and even if it is a word other than that, it is included in the scope of the present technology as long as it is a word that expresses an anti-anxiety effect, a sleep improvement effect, an antidepressant effect, a learning disability and / or a memory impairment improvement effect, etc. It goes without saying that Examples of such wording include indications based on various uses that make consumers aware of anti-anxiety effects, sleep-improving effects, anti-depressive effects, learning and/or memory-impairing effects, and the like. is.
- composition according to the present technology when used in feed, it can be prepared by adding the peptide according to the present technology to a known feed, or a new feed can be produced by mixing the peptide into feed ingredients. can also In addition, when the peptide according to the present technology is used in feed, it may be used as it is, after being concentrated, or after being processed into a solid, liquid, granular or powdered form.
- Raw materials for the feed include, for example, cereals such as corn, wheat, barley, and rye; brans such as bran, wheat bran, rice bran, and defatted rice bran; manufacturing lees such as corn gluten meal and corn jam meal; Animal feeds such as whey, fish meal, and bone meal; yeasts such as brewer's yeast; mineral feeds such as calcium phosphate and calcium carbonate; oils and fats; amino acids; Examples of the form of the feed include pet feed (for example, pet food), livestock feed, fish farm feed, and the like.
- the content or amount of the peptide according to the present technology in the composition according to the present technology is not particularly limited. is preferred.
- the administration or ingestion interval and the administration or ingestion period of the composition according to the present technology are not particularly limited.
- the peptide according to the present technology is believed to be capable of preventing, improving, or treating various diseases and symptoms associated with the serotonin 5-HT 1A receptor.
- the compositions can be used, for example, to treat, prevent and/or ameliorate depression, bipolar disorder, schizophrenia, anxiety, or sleep disorders.
- the present technology can also employ the following configuration.
- [1] Use of the following peptide (a) or (b) in an anti-anxiety composition.
- anti-anxiety composition Use of the peptide of (a) or (b) above for the production of
- [3] Use of the above peptide (a) or (b) for treatment, prevention and/or improvement of depression, bipolar disorder, schizophrenia, anxiety neurosis, or sleep disorder.
- a method for treating, preventing and/or improving depression, bipolar disorder, schizophrenia, anxiety neurosis, or sleep disorders comprising the peptide of (a) or (b) above as an active ingredient.
- Use of the above peptide (a) or (b) in a composition for improving learning disorders and/or memory disorders comprising the peptide of (a) or (b) above as an active ingredient.
- Production Example 1 Production of Peptide NLPPLT by Enzymatic Degradation of Whey Protein 1 kg of a commercially available whey protein concentrate was dissolved in 9 kg of purified water and sterilized at 75° C. for 15 seconds in a plate-type sterilizer. After that, sodium hydroxide was added to adjust the pH of the solution to 9.0, and then a protease was added for hydrolysis to obtain a solution containing NLPPLT. Thereafter, the enzyme was deactivated, concentrated by a conventional method, and dried to obtain about 1 kg of powdered whey protein hydrolyzate (hereinafter referred to as "WPH”) containing the peptide NLPPLT.
- WPH powdered whey protein hydrolyzate
- Test Example 1 Elevated Plus Maze Test An elevated plus maze consisting of a cross where two flat plates (arms) of 25 cm ⁇ 5 cm intersect was set at a height of 50 cm from the floor.
- One of the arms is a closed arm with a 15 cm high transparent enclosure, allowing mice to walk safely without fear of falling.
- the other arm is an open arm without such an enclosure, and since it has an open perimeter, mice that are afraid of heights usually do not like the open arm.
- anxiolytic treatment of mice tends to increase the time spent in open arms. Therefore, in the confirmation test of anxiolytic effects, the longer the mouse stays in the open arm or the more times the mouse enters the open arm, the higher the anxiolytic activity.
- Test Results Table 1 below shows the test results.
- the administration of WPH increased the time spent on the open arms and the number of times the animals entered the open arms, confirming that WPH has anxiolytic activity.
- peptide NLPPLT Since the administration of peptide NLPPLT increased the residence time on the open arm compared to the control, it was confirmed that peptide NLPPLT has anxiolytic activity.
- the dwell time on the open arms was reduced compared to administration of the peptide alone, at a rate comparable to the control. Became. Therefore, it was suggested that the action of the peptide NLPPLT was based on the action mediated by the activation of the serotonin 5-HT 1A receptor.
- the peptide NLPPLT since the peptide NLPPLT has an action mediated by activation of the serotonin 5-HT 1A receptor, it is not only an anxiolytic action but also one of the actions based on the activation of the serotonin 5-HT 1A receptor. It was also suggested that it is thought to have a sleep-improving effect.
- Test Example 2 Open field test An open field test was performed as a behavioral test used for screening anxiolytics. It utilizes the fact that administration of anxiolytics reduces the proportion of time that mice stay in the center of the field (hereinafter referred to as "staying time"). Behavior was observed for 5 minutes 30 minutes after administration.
- a circular field consisting of a plurality of concentric circles with the same center and different radii was used. The circle closest to the center of the field is taken as the center of the field, and the time for the mouse placed in the center of the field to stay in the center of the field is measured.
- the ratio (%) of staying time was calculated as an index of anxiolytic activity.
- Test Results Table 4 below shows the test results.
- peptide NLPPLT Since the administration of peptide NLPPLT increased the residence time compared to the control, it was confirmed that peptide NLPPLT has anxiolytic activity.
- Tail Suspension Test A tail suspension test used for screening antidepressants was performed. It is thought that when a mouse is suspended by its tail and placed under conditions in which it cannot escape, it will initially try to escape and move around, but over time it will despair and become immobile. On the other hand, mice treated with antidepressants show increased escape time and decreased immobility time. That is, when the immobility time is reduced, it is evaluated as having an antidepressant effect. Behavior was observed for 6 minutes 30 minutes after administration.
- Test Results Table 5 below shows the test results.
- WPH has antidepressant properties, since the administration of WPH reduced the duration of immobile behavior compared to controls.
- peptide NLPPLT Since the administration of peptide NLPPLT reduced the time of immobility manifestation compared to controls, it was confirmed that peptide NLPPLT has antidepressant properties.
- the action of peptide NLPPLT is based on the action mediated by AMPA receptor activation.
- AMPA receptors are known to be involved in antidepressant effects, which is consistent with the present peptide exhibiting antidepressant activity.
- this peptide exhibits memory impairment improving action and learning impairment improving action.
- the peptide according to the present technology can be used for anti-anxiety, sleep improvement, anti-depression, and improvement of learning and/or memory impairment.
- a composition containing the peptide as an active ingredient is useful for reducing anxiety symptoms, reducing mental stress, treating, preventing and/or improving depression, bipolar disorder, schizophrenia, anxiety neurosis, or sleep disorders. It is possible to use it in a wide range of fields such as pharmaceuticals or food and drink for the purpose.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(a)配列番号1に記載のアミノ酸配列
(b)配列番号1に記載のアミノ酸配列において、1若しくは数個のアミノ酸が置換、欠失、又は付加されたアミノ酸列
本技術に係るペプチドは、抗不安作用、睡眠改善作用、抗抑うつ作用、或いは学習障害及び/又は記憶障害改善作用を有していてよい。
本技術に係る組成物は、飲食品であってよい。
本技術に係る組成物は、医薬品であってよい。この場合、本技術に係る組成物は、うつ病、双極性障害、統合失調症、不安神経症、又は睡眠障害の治療、予防及び/又は改善に用いられてもよい。
なお、ここに記載された効果は、必ずしも限定されるものではなく、本明細書中に記載されたいずれかの効果であってもよい。
なお、以下に説明する実施形態は、本技術の代表的な実施形態の一例を示したものであり、これにより本技術の範囲が狭く解釈されることはない。
本技術に係るペプチドは、Asn-Leu-Pro-Pro-Leu-Thrで表されるアミノ酸配列(配列番号1)を有する。本技術において、Asn(N)はL-アスパラギン残基、Leu(L)はL-ロイシン残基、Pro(P)はL-プロリン残基、Thr(T)はL-トレオニン残基を示す。
また、本技術に係るペプチドは、配列番号1に記載のアミノ酸配列において、1若しくは数個のアミノ酸が置換、欠失、又は付加されたアミノ酸列を有する。この場合、置換、欠失、又は付加されるアミノ酸の数は、2個以下であることが好ましい。
原料蛋白質は、本技術に係るペプチドを構造上に含む蛋白質であって、適宜加水分解酵素で消化したときに本技術に係るペプチドが生成可能なものであれば、特に限定されない。前記蛋白質として、例えば、動物由来、植物由来や微生物由来のもの等が挙げられ、本技術では、これらの中でも、大量に入手可能なホエイ蛋白質が好ましい。
前記アルカリ剤又は酸剤としては、特に限定されず、医薬品又は飲食品に許容されるものを使用すればよい。アルカリ剤としては、例えば、水酸化ナトリウムや水酸化カルシウム等の水酸化物;炭酸カリウム等の炭酸塩などが挙げられ、これらは、アルカリ金属塩やアルカリ土類金属塩でもよい。また、酸剤としては、例えば、塩酸、リン酸等の無機酸;クエン酸、酢酸、ギ酸等の有機酸などが挙げられる。本技術では、これらのうち、適宜1種又は2種以上を用いることができる。
また、前記蛋白質を含有する溶液を、70~90℃で15秒~10分間程度加熱殺菌することが、雑菌汚染による変敗防止の点から好ましい。
このとき、前記加水分解酵素を添加した後、当該溶液を、酵素の種類に応じて適当な温度、例えば、30~60℃、好ましくは45~55℃に保持して、蛋白質の加水分解を開始する。
また、加水分解反応時間は、酵素反応の分解率をモニターしながら、好ましい分解率に達するまで反応を続ければよい。
前記加水分解酵素反応の停止は、例えば、加水分解液中の酵素の失活により行われ、常法による加熱失活処理により実施することができる。加熱失活処理の加熱温度と保持時間は、使用した酵素の熱安定性を考慮し、十分に失活できる条件を適宜設定することができるが、例えば、80~130℃の温度範囲で30分間~2秒間の保持時間で行うことができる。
本技術に係るペプチドの精製は、通常、オリゴペプチドの精製に用いられているのと同様の手法、例えば、イオン交換クロマトグラフィー、吸着クロマトグラフィー、逆相クロマトグラフィー、分配クロマトグラフィー、ゲル濾過クロマトグラフィー等の各種クロマトグラフィー、溶媒沈殿、塩析、2種の液相間での分配等の方法を適宜組み合わせることによって行うことができる。
本技術に係るペプチドの化学合成は、オリゴペプチドの合成に通常用いられている液相法又は固相法によって行うことができる。合成されたペプチドは必要に応じて脱保護され、未反応試薬や副生物等を除去して、本技術に係るペプチドを単離することが可能である。
このようなペプチドの合成は、例えば、市販のペプチド合成装置等を用いて行うことができる。目的とするペプチドが得られたことは、抗不安作用、睡眠改善作用、抗抑うつ作用、並びに学習障害及び/又は記憶障害の改善作用から選択されるいずれか一以上の作用を指標として確認することができる。
なお、本明細書において、「改善」とは、疾患、症状又は状態の好転;疾患、症状又は状態の悪化防止、遅延;疾患又は症状の進行の逆転、防止又は遅延をいい、「予防」とは、適用対象における疾患若しくは症状の発症の防止や遅延、又は適用対象の疾患若しくは症状の危険性の低下、健康の維持をいう。
なお、本明細書において、「非治療目的」とは、医療行為、すなわち、治療による人体への処置行為を含まない概念であり、例えば、美容行為、健康増進等が挙げられる。
本技術では、前述した本技術に係るペプチドを有効成分として含有する組成物も提供する。本技術に係る組成物は、製剤等の医薬品、飲食品、飼料等として用いることができる。また、本技術に係るペプチドは、これら各種組成物等の製造のために用いることができる。
また、本技術に係るペプチドを医薬品に利用する際には、そのまま、又は濃縮してから、或いは固体状、液体状、顆粒状又は粉末状に加工してから用いてもよい。
なお、製剤化は剤形に応じて、適宜、公知の方法により実施できる。
固形製剤の場合の担体としては、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、安定剤、矯味矯臭剤等が挙げられる。
なお、経口投与用の液剤の場合に使用する担体としては、水等の溶剤、矯味矯臭剤等が挙げられる。
また、本技術に係るペプチドを飲食品に利用する際には、そのまま、又は濃縮してから、或いは固体状、液体状、顆粒状又は粉末状に加工してから用いてもよい。
小麦粉製品としては、例えば、パン、マカロニ、スパゲッティ、めん類、ケーキミックス、から揚げ粉、パン粉等が挙げられる。
即席食品類としては、例えば、即席めん、カップめん、レトルト・調理食品、調理缶詰め、電子レンジ食品、即席スープ・シチュー、即席みそ汁・吸い物、スープ缶詰め、フリーズ・ドライ食品、その他の即席食品等が挙げられる。
農産加工品としては、例えば、農産缶詰め、果実缶詰め、ジャム・マーマレード類、漬物、煮豆類、農産乾物類、シリアル(穀物加工品)等が挙げられる。
水産加工品としては、例えば、水産缶詰め、魚肉ハム・ソーセージ、水産練り製品、水産珍味類、つくだ煮類等が挙げられる。
畜産加工品としては、例えば、畜産缶詰め・ペースト類、畜肉ハム・ソーセージ等が挙げられる。
油脂類としては、例えば、バター、マーガリン類、植物油等が挙げられる。
基礎調味料としては、例えば、しょうゆ、みそ、ソース類、トマト加工調味料、みりん類、食酢類等が挙げられ、前記複合調味料・食品類として、調理ミックス、カレーの素類、たれ類、ドレッシング類、めんつゆ類、スパイス類、その他の複合調味料等が挙げられる。
冷凍食品としては、例えば、素材冷凍食品、半調理冷凍食品、調理済冷凍食品等が挙げられる。
菓子類としては、例えば、キャラメル、キャンディー、チューインガム、チョコレート、クッキー、ビスケット、ケーキ、パイ、スナック、クラッカー、和菓子、米菓子、豆菓子、デザート菓子、その他の菓子等が挙げられる。
飲料類としては、例えば、炭酸飲料、天然果汁、果汁飲料、果汁入り清涼飲料、果肉飲料、果粒入り果実飲料、野菜系飲料、豆乳、豆乳飲料、コーヒー飲料、お茶飲料、粉末飲料、濃縮飲料、スポーツ飲料、栄養飲料、アルコール飲料、その他の嗜好飲料等が挙げられる。
前述した食品以外の市販食品としては、例えば、ベビーフード、ふりかけ、お茶漬けのり等が挙げられる。
また、本技術に係るペプチドを飼料に利用する際には、そのまま、又は濃縮してから、或いは固体状、液体状、顆粒状又は粉末状に加工してから用いてもよい。
前記飼料の形態としては、例えば、愛玩動物用飼料(例えば、ペットフード等)、家畜飼料、養魚飼料等が挙げられる。
また、本技術に係る組成物の投与又は摂取間隔、投与又は摂取期間も、特に限定されない。
〔1〕抗不安用組成物への、下記(a)又は(b)のペプチドの使用。
(a)配列番号1に記載のアミノ酸配列
(b)配列番号1に記載のアミノ酸配列において、1若しくは数個のアミノ酸が置換、欠失、又は付加されたアミノ酸列
〔2〕抗不安用組成物の製造のための、上記(a)又は(b)のペプチドの使用。
〔3〕うつ病、双極性障害、統合失調症、不安神経症、又は睡眠障害の治療、予防及び/又は改善のための、上記(a)又は(b)のペプチドの使用。
〔4〕上記(a)又は(b)のペプチドを有効成分とする、うつ病、双極性障害、統合失調症、不安神経症、又は睡眠障害の治療、予防及び/又は改善方法。
〔5〕睡眠改善用組成物への、上記(a)又は(b)のペプチドの使用。
〔6〕睡眠改善用組成物の製造のための、上記(a)又は(b)のペプチドの使用。
〔7〕抗抑うつ用組成物への、上記(a)又は(b)のペプチドの使用。
〔8〕抗抑うつ用組成物の製造のための、上記(a)又は(b)のペプチドの使用。
〔9〕学習障害及び/又は記憶障害の改善用組成物への、上記(a)又は(b)のペプチドの使用。
〔10〕学習障害及び/又は記憶障害の改善用組成物の製造のための、上記(a)又は(b)のペプチドの使用。
〔11〕下記(a)又は(b)のペプチドを用いた、不安、睡眠障害、抑うつ、学習障害、及び記憶障害からなる群より選ばれるいずれか1種以上の治療、予防及び/又は改善方法。
(a)配列番号1に記載のアミノ酸配列
(b)配列番号1に記載のアミノ酸配列において、1若しくは数個のアミノ酸が置換、欠失、又は付加されたアミノ酸列
〔12〕下記(a)又は(b)のペプチドを用いた、うつ病、双極性障害、統合失調症、及び不安神経症からなる群より選ばれるいずれか1種以上の疾患の治療、予防及び/又は改善方法。
(a)配列番号1に記載のアミノ酸配列
(b)配列番号1に記載のアミノ酸配列において、1若しくは数個のアミノ酸が置換、欠失、又は付加されたアミノ酸列
なお、以下に説明する実施例は、本技術の代表的な実施例の一例を示したものであり、これにより本技術の範囲が狭く解釈されることはない。
市販のホエイ蛋白質濃縮物1kgを9kgの精製水に溶解し、プレート型殺菌装置にて75℃で15秒間殺菌した。その後、水酸化ナトリウムを添加して溶液のpHを9.0に調整した後、たんぱく質分解酵素を添加して加水分解をして、NLPPLTを含む溶液を得た。その後、酵素を失活させ、常法により濃縮し、乾燥し、ペプチドNLPPLTを含有する粉末状の乳清蛋白質分解物(以下、「WPH」とする)約1kg得た。
NLPPLTはF-moc法により化学合成した。脱保護後に逆相HPLC(Waters 1525)で精製、凍結乾燥した。得られたペプチドはLCMSで分子量が合致していること
を確認した。
25cm×5cmの2つの平板(アーム)が交差する十字路からなる高架式十字迷路を床から50cmの高さに設置した。アームの一方は、高さ15cmの透明の囲いがあるクローズドアームであり、マウスは落下の不安を感じることなく安全に歩行する事ができる。もう一方のアームは、このような囲いのないオープンアームであり、周囲が開放されているため、高い場所を怖がるマウスは通常オープンアームを好まない。しかしながら、マウスへの抗不安処置によりオープンアームでの滞在時間が長くなる傾向がある。したがって、抗不安作用の確認試験においては、オープンアームでのマウスの滞在時間が長いほど、あるいは進入回数が多いほど抗不安活性が高くなる。
本願発明者らは、まず、製造例1で調製したWPHに関して、試験を行った。
雄性ddyマウスに試験の30分前に製造例1で調整したWPHを体重1kg当たり10mg、30mg、又は100mgとなる用量でそれぞれ投与し、その30分後にオープンアームとクローズドアームが交差する中央プラットフォーム上にマウスを置いて試験を行った(WPH投与群、n=6)。開始後5分間、オープンアーム上にマウスが滞在した累積時間(time in open arms)、オープンアームに進入した回数(visit to open arms)、いずれかのアームに進入した回数の総数(total visits)を記録した。
また、コントロールとして、試験物質である前記WPHを投与しない雄性ddyマウスでも同様の試験を実施した(コントロール群、n=6)。
下記表1に試験結果を示す。
本発明者らは、前記<1>の結果から、前記WPHに含まれるペプチドNLPPLTに着目し、該ペプチドについても試験を行った。
雄性ddyマウスに試験の30分前に製造例2で合成したペプチドNLPPLTを体重1kg当たり3μg又は10μgとなる用量で投与し、その30分後にオープンアームとクローズドアームが交差する中央プラットフォーム上にマウスを置いて試験を行った(ペプチドNLPPLT投与群、n=6)。開始後5分間、オープンアーム上にマウスが滞在した累積時間(time in open arms)、オープンアームに進入した回数(visit to open arms)、いずれかのアームに進入した回数の総数(total visits)を記録した。
また、コントロールとして、試験物質である前記ペプチドを投与しない雄性ddyマウスでも同様の試験を実施した(コントロール群、n=6)。
下記表2及び表3に試験結果を示す。
抗不安薬のスクリーニングに用いられる行動試験としてオープンフィールド試験を実施した。抗不安薬投与によりマウスがフィールドの中央に滞在する時間(以下、「滞在時間」と記す)の割合が低下することを利用する。投与30分後に5分間行動を観察した。なお、このオープンフィールド試験では、中心を同一とし半径が異なる複数の同心円からなる円形のフィールドを利用した。フィールドのうち最も中心側の円をフィールドの中央とし、このフィールドの中央に置かれたマウスが、フィールドの中央に滞在する時間が測定される。
本願発明者らは、ペプチドNLPPLTに着目して試験を行った。
雄性ddyマウスに試験の30分前に製造例2で合成したペプチドNLPPLTを体重1kg当たり10μg、30μg、又は100μgとなる用量でそれぞれ投与し、その30分後にマウスをフィールドの中央に置いて試験を行った(ペプチドNLPPLT投与群、n=5)。開始後5分間、滞在時間を記録した。
また、コントロールとして、試験物質である前記ペプチドを投与しない雄性ddyマウスでも同様の試験を実施した(コントロール群、n=5-6)。
下記表4に試験結果を示す。
抗うつ薬のスクリーニングに用いられる尾懸垂試験を実施した。マウスの尾を固定して吊り下げ、逃避不可能な条件下に置くと、初めは逃避を試みて動き回るが、時間が経つにうれて絶望し動かなくなると考えられる。一方、抗うつ薬を処置したマウスでは逃避行動時間が増加し無動時間が減少する。すなわち、無動時間が減少した際に、抗抑うつ効果ありと評価する。投与30分後に6分間行動を観察した。
本願発明者らは、まず、製造例1で調整したWPHに関して、試験を行った。
雄性ddyマウスに試験の30分前に製造例1で合成したWPHを体重1kg当たり1mg、10mg又は100mgとなる用量でそれぞれ投与し、その30分後にマウスの尾を固定して吊り上げ、試験を行った(WPH投与群、n=9-11)。開始後6分間、無動行動の発現時間を記録した。
また、コントロールとして、試験物質である前記ペプチドを投与しない雄性ddyマウスでも同様の試験を実施した(コントロール群、n=9-11)。
下記表5に試験結果を示す。
本願発明者らは、ペプチドNLPPLTに着目して試験を行った。
雄性ddyマウスに試験の30分前に製造例2で合成したペプチドNLPPLTを体重1kg当たり10μg、又は30μgとなる用量でそれぞれ投与し、その30分後にマウスの尾を固定して吊り上げ、試験を行った(ペプチドNLPPLT投与群、n=5-6)。開始後6分間、無動行動の発現時間を記録した。
また、コントロールとして、試験物質である前記ペプチドを投与しない雄性ddyマウスでも同様の試験を実施した(コントロール群、n=5-6)。
下記表6に試験結果を示す。
Claims (9)
- 下記(a)又は(b)のアミノ酸配列からなる、ペプチド。
(a)配列番号1に記載のアミノ酸配列
(b)配列番号1に記載のアミノ酸配列において、1若しくは数個のアミノ酸が置換、欠失、又は付加されたアミノ酸列 - 抗不安作用を有する、請求項1に記載のペプチド。
- 睡眠改善作用を有する、請求項1に記載のペプチド。
- 抗抑うつ作用を有する、請求項1に記載のペプチド。
- 学習障害及び/又は記憶障害の改善作用を有する、請求項1に記載のペプチド。
- 請求項1から5のいずれか一項に記載のペプチドを有効成分として含有する組成物。
- 前記組成物が飲食品である、請求項6に記載の組成物。
- 前記組成物が医薬品である、請求項6に記載の組成物。
- うつ病、双極性障害、統合失調症、不安神経症、又は睡眠障害の治療、予防及び/又は改善に用いられる、請求項8に記載の組成物。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280019836.9A CN116997561A (zh) | 2021-03-24 | 2022-03-24 | 肽及含有该肽作为有效成分的组合物 |
EP22775766.3A EP4317173A1 (en) | 2021-03-24 | 2022-03-24 | Peptide and composition containing peptide as active ingredient |
US18/281,350 US20240158440A1 (en) | 2021-03-24 | 2022-03-24 | Peptide and composition containing peptide as active ingredient |
JP2023509295A JPWO2022202985A1 (ja) | 2021-03-24 | 2022-03-24 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-050468 | 2021-03-24 | ||
JP2021050468 | 2021-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022202985A1 true WO2022202985A1 (ja) | 2022-09-29 |
Family
ID=83397360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/013912 WO2022202985A1 (ja) | 2021-03-24 | 2022-03-24 | ペプチド、及び該ペプチドを有効成分として含有する組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240158440A1 (ja) |
EP (1) | EP4317173A1 (ja) |
JP (1) | JPWO2022202985A1 (ja) |
CN (1) | CN116997561A (ja) |
WO (1) | WO2022202985A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023114846A1 (en) * | 2021-12-15 | 2023-06-22 | Digestome Therapeutics, Inc. | Uses of therapeutic peptides |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001136995A (ja) * | 1999-11-11 | 2001-05-22 | Calpis Co Ltd | トリペプチドの製造方法 |
JP2012031139A (ja) * | 2009-12-28 | 2012-02-16 | Calpis Co Ltd | 脳機能改善作用を有するペプチド |
JP2015519878A (ja) * | 2012-03-26 | 2015-07-16 | プロニュートリア・インコーポレイテッドPronutria, Inc. | 栄養断片、タンパク質、および方法 |
JP2016065038A (ja) * | 2014-08-18 | 2016-04-28 | 森永乳業株式会社 | プロリルオリゴペプチダーゼ阻害剤 |
JP2017008104A (ja) * | 2014-06-16 | 2017-01-12 | キリン株式会社 | 記憶学習機能及び/又は認知機能を増強するための組成物 |
JP2020198791A (ja) * | 2019-06-06 | 2020-12-17 | 雪印メグミルク株式会社 | 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料 |
-
2022
- 2022-03-24 JP JP2023509295A patent/JPWO2022202985A1/ja active Pending
- 2022-03-24 US US18/281,350 patent/US20240158440A1/en active Pending
- 2022-03-24 CN CN202280019836.9A patent/CN116997561A/zh active Pending
- 2022-03-24 WO PCT/JP2022/013912 patent/WO2022202985A1/ja active Application Filing
- 2022-03-24 EP EP22775766.3A patent/EP4317173A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001136995A (ja) * | 1999-11-11 | 2001-05-22 | Calpis Co Ltd | トリペプチドの製造方法 |
JP2012031139A (ja) * | 2009-12-28 | 2012-02-16 | Calpis Co Ltd | 脳機能改善作用を有するペプチド |
JP2015519878A (ja) * | 2012-03-26 | 2015-07-16 | プロニュートリア・インコーポレイテッドPronutria, Inc. | 栄養断片、タンパク質、および方法 |
JP2017008104A (ja) * | 2014-06-16 | 2017-01-12 | キリン株式会社 | 記憶学習機能及び/又は認知機能を増強するための組成物 |
JP2016065038A (ja) * | 2014-08-18 | 2016-04-28 | 森永乳業株式会社 | プロリルオリゴペプチダーゼ阻害剤 |
JP2020198791A (ja) * | 2019-06-06 | 2020-12-17 | 雪印メグミルク株式会社 | 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023114846A1 (en) * | 2021-12-15 | 2023-06-22 | Digestome Therapeutics, Inc. | Uses of therapeutic peptides |
Also Published As
Publication number | Publication date |
---|---|
CN116997561A (zh) | 2023-11-03 |
EP4317173A1 (en) | 2024-02-07 |
JPWO2022202985A1 (ja) | 2022-09-29 |
US20240158440A1 (en) | 2024-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6344796B2 (ja) | 高齢者用アルツハイマー型認知症改善剤 | |
JP6189994B2 (ja) | ジペプチジルペプチダーゼ−iv阻害用飲食品組成物 | |
JP2017031105A (ja) | 食後血糖値の上昇抑制を促進させる剤 | |
JP7358239B2 (ja) | エネルギー消費促進用組成物 | |
JP2015084694A (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
WO2022202985A1 (ja) | ペプチド、及び該ペプチドを有効成分として含有する組成物 | |
JP4395658B2 (ja) | コレステロール再上昇抑制用組成物およびその用法 | |
JP6369990B2 (ja) | 筋萎縮抑制剤及び筋萎縮抑制用飲食品 | |
WO2021059755A1 (ja) | 交感神経活性化用組成物 | |
JP2021126067A (ja) | Nampt発現促進組成物 | |
JP2021100412A (ja) | カゼイン酵素処理物及びその製造方法 | |
JP6778094B2 (ja) | カゼイン酵素分解物の製造方法及びカゼイン酵素分解物 | |
JP6345630B2 (ja) | 新規ペプチド及びその用途 | |
JP7344722B2 (ja) | 構成行為改善用組成物 | |
WO2024038888A1 (ja) | 組成物 | |
JP6964635B2 (ja) | 見当識改善用組成物 | |
WO2019160023A1 (ja) | 脳卒中予防用組成物 | |
JP6589011B2 (ja) | 脳機能障害改善用経口組成物 | |
CN112040972A (zh) | 用于降低血压和/或用于减少中性脂肪的组合物 | |
JP2017048124A (ja) | アミノペプチダーゼa阻害剤 | |
JP6797966B2 (ja) | 胃内酸性プロテアーゼ酵素活性阻害剤、ラクトフェリン組成物の製造方法、及びラクトフェリン組成物 | |
WO2022186290A1 (ja) | ジペプチジルペプチダーゼ-iv阻害剤 | |
WO2024071404A1 (ja) | 新規ペプチド、及び抗酸化用組成物 | |
JP2024033770A (ja) | 脳機能低下の予防、治療、又は軽減用組成物、及び、アミロイドβ凝集体の蓄積抑制のための組成物 | |
JP2015189672A (ja) | 概日リズム改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22775766 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280019836.9 Country of ref document: CN Ref document number: 2023509295 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18281350 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022775766 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022775766 Country of ref document: EP Effective date: 20231024 |